KRRO:NASDAQKorro Bio, Inc. Analysis
Data as of 2026-08-16 - not real-time
$13.28
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Korro Bio, Inc. is priced at $13.28 and its moving averages line up in bearish order, the shorter trailing the longer. It has lost 2.7% over the past 30 days. With RSI at 60.7 the momentum picture is approaching overbought, alongside a bullish MACD signal. Watch $9.76 as support and $13.93 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 52.1% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 62.4%, a beta of 2.88 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 52.1% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 62.4%, a beta of 2.88 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
CAMBRIDGE, Mass., July 10, 2026 GLOBE NEWSWIRE -- Korro Bio, Inc. Korro Nasdaq: KRRO a biopharmaceutical company...KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence...CAMBRIDGE, Mass., Aug. 14, 2026 GLOBE NEWSWIRE -- Korro Bio, Inc. Korro Nasdaq: KRRO , a biopharmaceutical company...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 12.61
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 12.61
- Analyst targets imply +52.1% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +52.1% versus the current price
- Negative return on equity of -97.7%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-3.0
ROE-97.69%
ROA-27.95%
Debt/Equity40.89
P/B Ratio1.9
Op. Cash Flow$-67948000
Free Cash Flow$-41390124
Industry P/E29.8
Technical Analysis
TrendBearish
RSI60.7
Support$9.76
Resistance$13.93
MA 20$11.70
MA 50$12.24
MA 200$12.61
MACDBullish
VolumeDecreasing
Fear & Greed Index95.98
Valuation
Target Price$20.20
Upside/Downside52.11%
GradeFair
TypeBlend
Risk Assessment
Beta2.88
Volatility62.37%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.